Literature DB >> 24373076

A brief history of hepatitis milestones.

Christian Trepo1.   

Abstract

Hepatitis has been a major plague of mankind. The history of the discovery of causative viruses is one of the most fascinating scientific adventures of this half century. Individualization of several types of hepatitis only emerged after world war two. Their identification has been associated with milestones which revolutionized medicine and public health. The discovery of HBV brought the first ever vaccine not prepared by tissue culture but initially directly from plasma and soon the first vaccine produced by genetic engineering. HBV vaccine proved to be the first "anti-cancer" vaccine by preventing hepatocellular carcinoma and practically eradicating it from childhood in Taiwan. Successful vaccines became also available for HAV and more recently HEV. The discovery of HCV in 1989 opened a new era since it was the first virus was identified by a direct molecular approach. Two billion people are infected with HBV and 350 million are chronic carriers of the virus. The extraordinary effectiveness of HBV vaccination was best illustrated in Taiwan and Singapore where in less than 2 decades HBs Ag carriers dropped from 9,1% to 2,7% and HCC from 27% to 17%. Successful development of nucleos(t)ides analogs make it now possible to fully control disease progression with a daily pill long term therapy. The progress in HCV therapy has been even more spectacular and successful treatment jumped from 6 % with interferon alone in 1986 to more than 80% in 2013 with triple combination therapies. Remarkably chronic hepatitis C is the only chronic disease which is curable. It will be soon possible to eradicate HCV infection with, an all oral, daily single pill (containing several molecules) for 3 to 6 months which will cure over 90% of patients. This unprecedented therapeutic victory benefiting hundred millions of people matches the triumphs over small pox, polio and tuberculosis. The next 10 years should undoubtedly witness cure or full control over all forms of acute and chronic hepatitis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Antivirals; HAV; HCV; HDV; Hepatitis B; Hepatitis C; History; Interferon; Liver; Nucleoside analogs; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24373076     DOI: 10.1111/liv.12409

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  22 in total

1.  Detection of hepatitis B virus infection: A systematic review.

Authors:  Mallika Ghosh; Srijita Nandi; Shrinwanti Dutta; Malay Kumar Saha
Journal:  World J Hepatol       Date:  2015-10-18

Review 2.  Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention.

Authors:  Jill Koshiol; Zhiwei Liu; Thomas R O'Brien; Allan Hildesheim
Journal:  Cancer Epidemiol       Date:  2018-02-13       Impact factor: 2.984

Review 3.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

4.  Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.

Authors:  Dawei Cai; Xiaohe Wang; Ran Yan; Richeng Mao; Yuanjie Liu; Changhua Ji; Andrea Cuconati; Haitao Guo
Journal:  Antiviral Res       Date:  2016-05-13       Impact factor: 5.970

Review 5.  Cancer immunoprevention.

Authors:  Olivera J Finn; Pamela L Beatty
Journal:  Curr Opin Immunol       Date:  2016-01-19       Impact factor: 7.486

6.  Public awareness and knowledge of liver health and diseases in Singapore.

Authors:  Chee-Kiat Tan; George Boon-Bee Goh; Jin Youn; Jacques Chak-Kwan Yu; Shikha Singh
Journal:  J Gastroenterol Hepatol       Date:  2021-03-30       Impact factor: 4.369

Review 7.  Update on Hepatitis B Virus Infection: Focus on Treatment.

Authors:  Stephanos J Hadziyannis
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

Review 8.  Viral Interactions with Adaptor-Protein Complexes: A Ubiquitous Trait among Viral Species.

Authors:  Ivana Strazic Geljic; Paola Kucan Brlic; Lucija Musak; Dubravka Karner; Andreja Ambriović-Ristov; Stipan Jonjic; Peter Schu; Tihana Lenac Rovis
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  Recent Advances in Hepatitis B Treatment.

Authors:  Georgia-Myrto Prifti; Dimitrios Moianos; Erofili Giannakopoulou; Vasiliki Pardali; John E Tavis; Grigoris Zoidis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01

10.  Predictors for Early Identification of Hepatitis C Virus Infection.

Authors:  Mei-Hua Tsai; Kuei-Hsiang Lin; Kuan-Tsou Lin; Chi-Ming Hung; Hung-Shiang Cheng; Yu-Chang Tyan; Hui-Wen Huang; Bintou Sanno-Duanda; Ming-Hui Yang; Shyng-Shiou Yuan; Pei-Yu Chu
Journal:  Biomed Res Int       Date:  2015-08-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.